A dose-linked mental health signal for semaglutide
A large EHR-based preprint links semaglutide to lower rates of many neuropsychiatric diagnoses, with a ‘legacy’ signal that tracks maximum achieved dose more than weight loss.
Tag
GLP-1
GLP-1 drugs are the center of the modern weight-loss and diabetes conversation. This tag collects plain-language explainers and research updates about what these medicines do, what the evidence says, and what still isn’t known.
Start here
GLP‑1 drugs and atrial fibrillation risk
A new observational study links GLP‑1 therapy to lower atrial fibrillation risk even when people do not lose weight, with the strongest signal reported for semaglutide.
GLP‑1 plus SGLT2 in fatty liver disease
A large real-world analysis links GLP‑1 plus SGLT2 combination therapy to lower rates of major liver and cardiovascular events in people with fatty liver disease and type 2 diabetes.
Rosuvastatin may briefly blunt post-meal GLP‑1
A translational study links cholesterol-pathway inhibition (HMGCR/rosuvastatin) to lower acute GLP‑1 secretion in gut cells and mice, offering a plausible mechanism behind statins’ mild diabetes signal.
GLP‑1 drugs during chemo: the monitoring gap
A new supportive-care commentary argues that as GLP‑1 drugs become common, cancer treatment teams may need routine nutrition and body-composition monitoring to avoid avoidable toxicity and dose changes.
Why SNAC’s chemistry may be the hidden variable in oral peptide pills
A new mechanistic study shows SNAC, the absorption enhancer used in oral semaglutide, changes state with pH, salts, bile, and co-medications—conditions that may shape oral peptide consistency.
GLP‑1 use before burns linked to lower mortality
A large matched TriNetX study found prior GLP‑1 receptor agonist exposure was associated with fewer infections, less ICU care, and lower mortality after smaller thermal burns, but it cannot prove cause and effect.
A new look at GLP‑1s and suicidality risk
A large register study using two comparator cohorts plus a self-controlled design found no increased rate of suicide or suicide attempts after starting GLP‑1 receptor agonists.
A neural clue for GLP-1 drugs’ heart rate bump
In an in vitro rat brainstem-spinal cord setup, exendin-4 increased sympathetic nerve activity and depolarized key neurons, supporting a direct neural route for GLP-1 receptor agonist tachycardia.
A five-minute sublingual window for a GLP‑1 peptide
In diabetic mice, a long-acting, fatty-acid–conjugated GLP-1 receptor agonist showed measurable effects when held under the tongue for about five minutes after the team tuned pH and excipients.
An umbrella review asks: do GLP‑1 drugs help heart failure?
A 2026 umbrella review of prior meta-analyses reports GLP‑1 receptor agonists are associated with lower major adverse cardiovascular events and less ‘worsening heart failure’, plus a small improvement in 6‑minute walk distance. Mortality and heart-failure hospitalization results were not clearly improved, and evidence certainty ranged low to moderate.
GLP-1 drugs and thyroid labs: a quiet monitoring gap
A Medicare target-trial emulation found similar thyroid-stimulating hormone (TSH) testing patterns after GLP-1 receptor agonist initiation versus SGLT-2 inhibitors in older adults on stable levothyroxine, despite weight loss often changing thyroid hormone requirements.
A new tirzepatide safety meta-analysis, focused on higher-risk patients
A systematic review and meta-analysis of 21 placebo-controlled trials in patients at increased cardiovascular risk found no clear difference in serious adverse events with tirzepatide, while gastrointestinal side effects remained more common. Mortality evidence was sparse.